Article Text

Download PDFPDF
Treatment of diffuse subretinal fibrosis uveitis with rituximab
  1. Kurt Spiteri Cornish1,
  2. Lucia Kuffova1,2,
  3. John V Forrester2,3
  1. 1Clinical Ophthalmology Department, NHS Grampian, Aberdeen Royal Infirmary, Aberdeen, UK
  2. 2Section of Immunology, Inflammation and Infection (3I's) (Ocular Immunology), Division of Applied Medicine, School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK
  3. 3Immunology Program, Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, Western Australia, Australia
  1. Correspondence to Dr Kurt Spiteri Cornish, Ophthalmology Department, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, UK; kspitericornish{at}


Diffuse subretinal fibrosis uveitis (DUS) syndrome is a rare form of granulomatous multifocal choroiditis (MFC) characterised by enlarging areas of subretinal fibrosis (SRF) which coalesce with subsequent macular involvement and visual loss. First described by Palestine, DUS carries a poor visual prognosis despite use of high-dose corticosteroids and systemic immunosuppression. We report two cases of bilateral DUS successfully treated with rituximab. We believe given the B-cell predominance in the underlying pathogenesis of the disease, rituximab should be considered first line in the management of this potentially devastating disease.

  • Immunology
  • Inflammation
  • Retina

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.